4q1n
From Proteopedia
(Difference between revisions)
| (One intermediate revision not shown.) | |||
| Line 1: | Line 1: | ||
==Structure-based design of 4-hydroxy-3,5-substituted piperidines as direct renin inhibitors== | ==Structure-based design of 4-hydroxy-3,5-substituted piperidines as direct renin inhibitors== | ||
| - | <StructureSection load='4q1n' size='340' side='right' caption='[[4q1n]], [[Resolution|resolution]] 2.09Å' scene=''> | + | <StructureSection load='4q1n' size='340' side='right'caption='[[4q1n]], [[Resolution|resolution]] 2.09Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[4q1n]] is a 2 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[4q1n]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Q1N OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4Q1N FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2Y9:(3S,4R,5R)-N-CYCLOPROPYL-N-[(2R)-1-ETHOXY-4-METHYLPENTAN-2-YL]-4-HYDROXY-N-[5-(PROPAN-2-YL)PYRIDIN-2-YL]PIPERIDINE-3,5-DICARBOXAMIDE'>2Y9</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.09Å</td></tr> |
| - | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2Y9:(3S,4R,5R)-N-CYCLOPROPYL-N-[(2R)-1-ETHOXY-4-METHYLPENTAN-2-YL]-4-HYDROXY-N-[5-(PROPAN-2-YL)PYRIDIN-2-YL]PIPERIDINE-3,5-DICARBOXAMIDE'>2Y9</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr> | |
| - | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4q1n FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4q1n OCA], [https://pdbe.org/4q1n PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4q1n RCSB], [https://www.ebi.ac.uk/pdbsum/4q1n PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4q1n ProSAT]</span></td></tr> | |
| - | + | ||
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | |
</table> | </table> | ||
== Disease == | == Disease == | ||
| - | [ | + | [https://www.uniprot.org/uniprot/RENI_HUMAN RENI_HUMAN] Defects in REN are a cause of renal tubular dysgenesis (RTD) [MIM:[https://omim.org/entry/267430 267430]. RTD is an autosomal recessive severe disorder of renal tubular development characterized by persistent fetal anuria and perinatal death, probably due to pulmonary hypoplasia from early-onset oligohydramnios (the Potter phenotype).<ref>PMID:16116425</ref> Defects in REN are the cause of familial juvenile hyperuricemic nephropathy type 2 (HNFJ2) [MIM:[https://omim.org/entry/613092 613092]. It is a renal disease characterized by juvenile onset of hyperuricemia, slowly progressive renal failure and anemia.<ref>PMID:19664745</ref> |
== Function == | == Function == | ||
| - | [ | + | [https://www.uniprot.org/uniprot/RENI_HUMAN RENI_HUMAN] Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney. |
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 23: | Line 21: | ||
</div> | </div> | ||
<div class="pdbe-citations 4q1n" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 4q1n" style="background-color:#fffaf0;"></div> | ||
| + | |||
| + | ==See Also== | ||
| + | *[[Renin|Renin]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| - | [[Category: | + | [[Category: Homo sapiens]] |
| - | [[Category: | + | [[Category: Large Structures]] |
| - | [[Category: Arcy | + | [[Category: D'Arcy A]] |
| - | [[Category: Irie | + | [[Category: Irie O]] |
| - | [[Category: Schiering | + | [[Category: Schiering N]] |
| - | [[Category: Yokokawa | + | [[Category: Yokokawa F]] |
| - | + | ||
| - | + | ||
| - | + | ||
Current revision
Structure-based design of 4-hydroxy-3,5-substituted piperidines as direct renin inhibitors
| |||||||||||
